Odd Lilleng Gammelgaard

6PUBLICATIONS
21CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 31, 2026
ATAD2B governs epigenetic silencing of the epithelial program to fuel cancer metastasis and neuronal migration.

|Dec 04, 2025
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trial.

Odd Lilleng Gammelgaard, Sidse Ehmsen, Anne Marie Bak Jylling

|Jan 06, 2024
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis.

Odd L Gammelgaard, Mikkel G Terp, Alexei F Kirkin

|Sep 12, 2022
Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity.

Odd L Gammelgaard, Mikkel G Terp, Christian Renn

|Aug 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.

Carla L Alves, Sidse Ehmsen, Mikkel G Terp

Pageof 1

Frequent Collaborators

6 joint publications

Henrik J Ditzel

3 joint publications

Mikkel G Terp

2 joint publications

Carla L Alves

2 joint publications

Sidse Ehmsen